Feasibility of EBUS-TBNA for the molecular characterization of non-small cell lung cancer
Sousa,Vitor
DOI: https://doi.org/10.36416/1806-3756/e20230193
2024-05-29
Jornal Brasileiro de Pneumologia
Abstract:The accurate diagnosis of lung cancer (LC) relies on histopathological classification (HC) and molecular characterization (MC) for targeted therapies. 1 1 Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(5):497-530. https://doi.org/10.6004/jnccn.2022.0025 https://doi.org/10.6004/jnccn.2022.0025... Clinicians that deal with LC face the dilemma of how to apply minimally invasive interventions that yield large and well-preserved samples suitable for the demands of the histopathologist and the molecular geneticist. A milestone in this pathway has been achieved with the introduction of EBUS-TBNA, which is currently the first-choice procedure for mediastinal staging of LC. 2 2 Vilmann P, Clementsen PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) [published correction appears in Endoscopy. 2015 Jun;47(6):c1. Vasquez-Sequeiros, Enrique [corrected to Vazquez-Sequeiros, Enrique]]. Endoscopy. 2015;47(6):545-559. https://doi.org/10.1055/s-0034-1392040 https://doi.org/10.1055/s-0034-1392040... , 3 3 Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-285. https://doi.org/10.1097/JTO.0b013e318206a221 https://doi.org/10.1097/JTO.0b013e318206... On the other hand, MC of non-small cell LC (NSCLC) is a growing field of research with diverse strategies and heterogenous results. 4 4 Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321-346. https://doi.org/10.5858/arpa.2017-0388-CP https://doi.org/10.5858/arpa.2017-0388-C... 5 Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol. 2014;32(32):3673-3679. https://doi.org/10.1200/JCO.2014.57.3055 https://doi.org/10.1200/JCO.2014.57.3055... 6 Labarca G, Folch E, Jantz M, Mehta HJ, Majid A, Fernandez-Bussy S. Adequacy of Samples Obtained by Endobronchial Ultrasound with Transbronchial Needle Aspiration for Molecular Analysis in Patients with Non-Small Cell Lung Cancer. Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2018;15(10):1205-1216. https://doi.org/10.1513/AnnalsATS.201801-045OC https://doi.org/10.1513/AnnalsATS.201801... - 7 7 Karadzovska-Kotevska M, Brunnström H, Kosieradzki J, Ek L, Estberg C, Staaf J, et al. Feasibility of EBUS-TBNA for histopathological and molecular diagnostics of NSCLC-A retrospective single-center experience. PLoS One. 2022;17(2):e0263342. https://doi.org/10.1371/journal.pone.0263342 https://doi.org/10.1371/journal.pone.026... In this study we aimed to evaluate the current clinical practice of a large oncology referral centre concerning the feasibility of EBUS-TBNA-derived samples for MC of NSCLC. We conducted a retrospective analysis (between January of 2019 and December of 2021) of all patients who underwent EBUS-TBNA for diagnosis and/or staging of NSCLC whose samples proceeded to MC. EBUS-TBNA was performed under general anesthesia with a BF-UC180F endoscope (Olympus, Tokyo, Japan) and 21G needles (ViziSh -Abstract Truncated-
respiratory system